Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study
Abstract Objective Recent preclinical and retrospective clinical evidence shows that androgen receptor (AR)-mediated signals have significant roles in development of non-muscle invasive bladder cancer (NMIBC). Here, we conducted a single-center, phase I study to assess the feasibility and efficacy o...
Saved in:
Main Authors: | Takashi Kawahara, Shuya Kandori, Takahiro Kojima, Bryan J. Mathis, Masanobu Shiga, Hiroyuki Nishiyama |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Research Notes |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13104-025-07128-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Variations in the diagnostic performance of transurethral resection of bladder tumor with photodynamic diagnosis according to surgical experience: A retrospective, single-center study
by: Shuhei Suzuki, et al.
Published: (2025-02-01) -
Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01) -
A novel bladder cancer surveillance schedule using bladder Cx for patients on annual surveillance
by: Arjun Guduguntla, et al.
Published: (2025-01-01) -
A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer
by: Xiannan Meng, et al.
Published: (2025-01-01) -
Trimodal organ‑preserving treatment of muscle‑invasive bladder cancer
by: A. V. Troianov, et al.
Published: (2023-03-01)